Improved uptake of SGLT2i in people with CKD has the potential to substantially reduce the incidence of kidney failure in Australia

Implementation now critical to realising these population level benefits

Our new paper #openaccess in The Lancet Reg Health-West Pacific

thelancet.com/journals/lanwp…

I'm honoured and excited to have been selected for the ISN Emerging Leaders Program, to collaborate with inspiring nephrologists from around the world to work towards better global kidney outcomes. Thanks Int Society of Nephrology!

The ISN-ACT Clinical Trials Toolkit is an #OpenAccess , an online resource to assist with trial design, study conduct, data management, data analysis, and publication. Access the Toolkit here: theisn.org/in-action/rese… #NephTwitter #ClinicalTrial #ThisIsISN

Thanks for joining today's Space. Thanks to our experts Meg Jardine @[email protected], Muh Geot, & Daniel O'Hara, the GTF team, & our hosts manjusha yadla, & Fernanda Arce-Amaré.

The recording will be available on Twitter for 30 days. After that, listen to it at the ISN Academy.
twitter.com/i/spaces/1kvKp…

Meg Jardine @[email protected] Muh Geot Mohamed E. Elrggal Daniel O'Hara ISN Education manjusha yadla Fernanda Arce-Amaré Michele Provenzano Anastasiia Zykova Angela Wang Mike Walsh Roberto Pecoits-Filho Debasish Banerjee Alex Gallagher David C Wheeler Rhys Evans Sandrine Damster Masaomi Nangaku Fergus Caskey aminu bello Bénédicte Stengel Shuchi Anand Agnes Fogo Augusto Cesar S Santos Jr Michelle Wong Sabine Karam Viviane Calice-Silva Anna Francis Titi Chen Renal Uitm Georges Nakhoul Rahul Chanchlani Eranga Wijewickrama #ISNGTF 𝗧𝗪𝗜𝗧𝗧𝗘𝗥 𝗦𝗣𝗔𝗖𝗘: TESTING Randomized Clinical Trial

When compared to the placebo, the cumulative incidence of a 40% drop in GFR, kidney failure, and death due to kidney disease was lower in the MP group, demonstrating its efficacy

🔗 twitter.com/i/spaces/1kvKp…

I’m going to Int Society of Nephrology #TwitterSpace for the #ISNGTF on the TESTING Randomized Clinical Trial, with Meg Jardine @[email protected], Muh Geot, Daniel O'Hara, and our host, manjusha yadla.

Mohamed E. Elrggal, Augusto Cesar S Santos Jr, Roberto Pecoits-Filho, Viviane Calice-Silva, Basu Gopal are you joining too?
twitter.com/i/spaces/1kvKp…

I'm excited for our first ISN Global Trials Focus Twitter Space this week, to discuss some behind-the-scenes of the GTF and to explore the practice-changing TESTING trial with Prof Meg Jardine and A/Prof Muh Geot Wong, study investigators and experts in the field. Please join us!

𝗦𝗔𝗩𝗘 𝗧𝗛𝗘 𝗗𝗔𝗧𝗘 for the #ISNGTF first Twitter Space: The TESTING Randomized Clinical Trial
🗣️ Meg Jardine @[email protected] Muh Geot Mohamed E. Elrggal Daniel O'Hara
👥 manjusha yadla Fernanda Arce-Amaré
🗓️ November 17
🕓 4 pm EST 🕙 10 pm CET
🗓️ November 18
🕗 8 am AEDT
🔗 twitter.com/i/spaces/1kvKp…

In this randomized trial, the discontinuation of renin–angiotensin system inhibitors in patients with advanced chronic kidney disease did not lead to a significant between-group difference in the long-term rate of decline in the eGFR. #KidneyWk nej.md/3UwMSlR

The ISN-ACT Clinical Trials Toolkit is an #OpenAccess , an online resource to assist with trial design, study conduct, data management, data analysis, and publication. Access the Toolkit here: theisn.org/in-action/rese…

Many excellent trials this month, the #ISNGTF June's trial of the month goes to the Advance Care Planning Coaching in CKD Clinics, a pragmatic RCT, AJKD by Dale Lupu et al. See the latest edition of the ISN GTF for more info.

An excellent review by Dr Brendon Neuen and colleagues assessing the benefits and limitations of endothelin receptor antagonists in chronic kidney disease

An interesting article on an important topic, by the brilliant Dr Jenny HC Chen

New Comment! Ewout J. Hoorn, Matti Marklund & Jason Wu discuss #salt substitution: opportunities and challenges for nephrology go.nature.com/3bxoSNV

SGLT2 inhibitors and MRAs confer kidney and cardiovascular protection in patients with CKD. This study found that combined SGLT2 inhibitor and mineralocorticoid receptor antagonist treatment lowered albuminuria by more than half in patients with CKD bit.ly/j2022020207

Ever heard of the Int Society of Nephrology global trial focus #ISNGTF ?
Here is a tweetorial to let you know more:
The #ISNGTF is a subgroup of the #ISNACT group, who are identifying and summarizing recent interesting trials in Nephrology.

Meg Jardine @[email protected] Angela Wang David C Wheeler Mohamed E. Elrggal Brendan Augusto Cesar S Santos Jr Abduzhappar Gaipov Debasish Banerjee Ragada El-Damanawi Alex Gallagher Rainer Oberbauer JAMA Internal Medicine A group of UK researchers examined the effect of regular Acetaminophen Use on Blood Pressure in People With Hypertension: The PATH-BP Trial published in Circulation. VA by Husam Alzayer for the @nephjc. See the #ISNGTF latest edition ➡️ theisn.org/in-action/rese…

Meg Jardine @[email protected] Angela Wang David C Wheeler Mohamed E. Elrggal Brendan Augusto Cesar S Santos Jr Abduzhappar Gaipov Debasish Banerjee Ragada El-Damanawi Alex Gallagher The ISN-GTF trial of the month goes to Reindl-Schwaighofer & Rainer Oberbauer for their RCT showing that heterologous booster is not better than a 3rd mRNA dose in 200 kidney transplant recipients. JAMA Internal Medicine. See the #ISNGTF latest edition ➡️ theisn.org/in-action/rese…

The ISN-ACT Global Trials Focus #ISNGTF team has collected and published a new list of randomized research from nephrologists around the world for March. Each trial is reviewed in context and the risk of bias in seven key areas is assessed ➡ theisn.org/in-action/rese…

Brilliant article sharing powerful insights into the global challenges in diabetes care, and the road ahead

Shocking to read that developing countries account for 80% of people with DM but only 1% of global DM expenditure, and half of those with T1DM die from lack of basic care